| 1 | Impact of Treatment on Inflammatory Choroidal Neovascularization in Patients with Sarcoidosis. (Schulgit MJ, Srivastava SK, Castilho S Barbosa G, Duphare C, Delaney A, Mammo DA, Lowder CY, Baynes K, Lowe A, Lin P, Sharma S) Ocul Immunol Inflamm 2026 Feb;34(2):276-283 |
| 1 | Lapses in Care Among Patients Assigned to Ranibizumab for Proliferative Diabetic Retinopathy: A Post Hoc Analysis of a Randomized Clinical Trial. (Maguire MG, Liu D, Bressler SB, Friedman SM, Melia M, Stockdale CR, Glassman AR, Sun JK, DRCR Retina Network) JAMA Ophthalmol 2021 Dec 01;139(12):1266-1273 24 Citations |
| 1 | Long-term full-field and multifocal electroretinographic changes after treatment with ranibizumab in patients with diabetic macular edema. (Yigit K, Inan ÜÜ, Inan S, Dogan M, Yavas GF, Cetinkaya E) Int Ophthalmol 2021 Apr;41(4):1487-1501 6 Citations |
| 1 | Visual Field Changes Over 5 Years in Patients Treated With Panretinal Photocoagulation or Ranibizumab for Proliferative Diabetic Retinopathy. (Maguire MG, Liu D, Glassman AR, Jampol LM, Johnson CA, Baker CW, Bressler NM, Gardner TW, Pieramici D, Stockdale CR, Sun JK, DRCR Retina Network) JAMA Ophthalmol 2020 Mar 01;138(3):285-293 52 Citations |
| 1 | Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. (Gross JG, Glassman AR, Liu D, Sun JK, Antoszyk AN, Baker CW, Bressler NM, Elman MJ, Ferris FL 3rd, Gardner TW, Jampol LM, Martin DF, Melia M, Stockdale CR, Beck RW, Diabetic Retinopathy Clinical Research Network) JAMA Ophthalmol 2018 Oct 01;136(10):1138-1148 371 Citations |
| 1 | Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema. (Jampol LM, Glassman AR, Liu D, Aiello LP, Bressler NM, Duh EJ, Quaggin S, Wells JA, Wykoff CC, Diabetic Retinopathy Clinical Research Network) Ophthalmology 2018 Jul;125(7):1054-1063 37 Citations |
| 1 | Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial. (Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Altaweel M, Berinstein DM, SCORE2 Investigator Group) JAMA Ophthalmol 2018 Apr 01;136(4):337-345 39 Citations |
| 1 | PANRETINAL PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Comparison of Peripapillary Retinal Nerve Fiber Layer Thickness in a Randomized Clinical Trial. (Jampol LM, Odia I, Glassman AR, Baker CW, Bhorade AM, Han DP, Jaffe GJ, Melia M, Bressler NM, Tanna AP, Diabetic Retinopathy Clinical Research Network) Retina 2019 Jan;39(1):69-78 13 Citations |
| 1 | Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial. (Jampol LM, Glassman AR, Bressler NM, Wells JA, Ayala AR, Diabetic Retinopathy Clinical Research Network) JAMA Ophthalmol 2016 Dec 01;134(12) 57 Citations |
| 2 | NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH ADVANCED VISUAL LOSS TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: Clinical Outcome and Prognostic Indicators. (Vogel RN, Davis DB, Kimura BH, Rathinavelu S, Graves GS, Szabo A, Han DP) Retina 2017 Feb;37(2):257-264 8 Citations |
| 1 | Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. (Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, Brucker AJ, Ferris FL, Hampton GR, Jhaveri C, Melia M, Beck RW, Diabetic Retinopathy Clinical Research Network) Ophthalmology 2016 Jun;123(6):1351-9 888 Citations |
| 1 | Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. (Wells JA, Glassman AR, Jampol LM, Aiello LP, Antoszyk AN, Baker CW, Bressler NM, Browning DJ, Connor CG, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW, Diabetic Retinopathy Clinical Research Network) JAMA Ophthalmol 2016 Feb;134(2):127-34 67 Citations |
| 1 | Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. (Bressler SB, Almukhtar T, Bhorade A, Bressler NM, Glassman AR, Huang SS, Jampol LM, Kim JE, Melia M, Diabetic Retinopathy Clinical Research Network Investigators) JAMA Ophthalmol 2015 May;133(5):589-97 75 Citations |
| 1 | Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. (Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW) N Engl J Med 2015 Mar 26;372(13):1193-203 1441 Citations |
| 1 | Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. (Bressler SB, Qin H, Melia M, Bressler NM, Beck RW, Chan CK, Grover S, Miller DG, Diabetic Retinopathy Clinical Research Network) JAMA Ophthalmol 2013 Aug;131(8):1033-40 106 Citations |
| 1 | Age-related macular degeneration, anti-VEGF therapy, and ophthalmic imaging: is there a best practice? (Han DP) JAMA Ophthalmol 2013 Sep;131(9):1124-6 7 Citations |
| 1 | Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. (Weinberg DV, Shapiro H, Ehrlich JS) Ophthalmology 2013 Jun;120(6):1278-82 14 Citations |
| 1 | Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. (Diabetic Retinopathy Clinical Research Network*) JAMA Ophthalmol 2013 Mar;131(3):283-93 95 Citations |
| 1 | Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. (Busbee BG, Ho AC, Brown DM, Heier JS, Suñer IJ, Li Z, Rubio RG, Lai P, HARBOR Study Group) Ophthalmology 2013 May;120(5):1046-56 486 Citations |
| 1 | Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. (Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL 3rd, Friedman SM, Glassman AR, Miller KM, Scott IU, Stockdale CR, Sun JK) Ophthalmology 2010 Jun;117(6):1064-1077.e35 1321 Citations |
| 1 | Ranibizumab for coloboma-related choroidal neovascular membrane in a child. (Goodwin P, Shields CL, Ramasubramanian A, Brown GC, Shields JA) J AAPOS 2009 Dec;13(6):616-7 18 Citations |
| 3 | Combined intravitreal anti-VEGF and verteporfin photodynamic therapy for juxtafoveal and extrafoveal choroidal neovascularization as an alternative to laser photocoagulation. (Han DP, McAllister JT, Weinberg DV, Kim JE, Wirostko WJ) Eye (Lond) 2010 Apr;24(4):713-6 20 Citations |
| 1 | Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. (Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J, Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration (ANCHOR) Research Group) Arch Ophthalmol 2009 Jan;127(1):13-21 87 Citations |
| 1 | Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. (Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, ANCHOR Study Group) Ophthalmology 2009 Jan;116(1):57-65.e5 1280 Citations |
| 1 | Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. (Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR, MARINA Study Group) Arch Ophthalmol 2007 Nov;125(11):1460-9 212 Citations |
| 1 | Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. (Kaiser PK, Blodi BA, Shapiro H, Acharya NR, MARINA Study Group) Ophthalmology 2007 Oct;114(10):1868-75 207 Citations |
| 1 | Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. (Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR, MARINA Study Group) Ophthalmology 2007 Feb;114(2):246-52 387 Citations |
| 1 | Ranibizumab versus verteporfin for neovascular age-related macular degeneration. (Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, ANCHOR Study Group) N Engl J Med 2006 Oct 05;355(14):1432-44 3397 Citations |
